Search research articles
Contact Us
Filters
Showing results (171-180 of 182) with videos related to
Page
of 19
Sort By:
Molecular Genetics and Metabolism
|
May 24, 2016
A phase 1/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA
Simon A Jones, Catherine Breen, Fiona Heap, et al.
Nuclear Medicine and Biology
|
August 29, 2006
Radiosynthesis and biodistribution of a histamine H3 receptor antagonist 4-[3-(4-piperidin-1-yl-but-1-ynyl)-[11C]benzyl]-morpholine: evaluation of a potential PET ligand
Anu J Airaksinen, Jill A Jablonowski, Margreet van der Mey, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 17, 2006
Dual serotonin transporter/histamine H3 ligands: Optimization of the H3 pharmacophore
John M Keith, Leslie A Gomez, Michael A Letavic, et al.
European Journal of Medicinal Chemistry
|
July 7, 2009
Heterocyclic replacement of the central phenyl core of diamine-based histamine H3 receptor antagonists
Devin M Swanson, Chandra R Shah, Brian Lord, et al.
European Journal of Pharmacology
|
September 4, 2007
Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor
Ann J Barbier, Leah Aluisio, Brian Lord, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 7, 2007
Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors
Kiev S Ly, Michael A Letavic, John M Keith, et al.
Molecular Pharmacology
|
July 20, 2002
Behavioral characterization of mice lacking histamine H(3) receptors
Hiroshi Toyota, Christine Dugovic, Muriel Koehl, et al.
Molecular Genetics and Metabolism
|
May 3, 2016
Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions
Elsa Shapiro, Jessica Bernstein, Heather R Adams, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
April 30, 2023
Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double-blind, placebo-controlled phase 1/2 clinical study
S M Rowe, J B Zuckerman, D Dorgan, et al.
The New England Journal of Medicine
|
September 5, 2019
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency
Rachael F Grace, Christian Rose, D Mark Layton, et al.
Page
of 19
Search research articles
Search
Showing results (171-180 of 182) with videos related to
Sort By:
Page
of 19
Molecular Genetics and Metabolism
|
May 24, 2016
A phase 1/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA
Simon A Jones, Catherine Breen, Fiona Heap, et al.
Nuclear Medicine and Biology
|
August 29, 2006
Radiosynthesis and biodistribution of a histamine H3 receptor antagonist 4-[3-(4-piperidin-1-yl-but-1-ynyl)-[11C]benzyl]-morpholine: evaluation of a potential PET ligand
Anu J Airaksinen, Jill A Jablonowski, Margreet van der Mey, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 17, 2006
Dual serotonin transporter/histamine H3 ligands: Optimization of the H3 pharmacophore
John M Keith, Leslie A Gomez, Michael A Letavic, et al.
European Journal of Medicinal Chemistry
|
July 7, 2009
Heterocyclic replacement of the central phenyl core of diamine-based histamine H3 receptor antagonists
Devin M Swanson, Chandra R Shah, Brian Lord, et al.
European Journal of Pharmacology
|
September 4, 2007
Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor
Ann J Barbier, Leah Aluisio, Brian Lord, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 7, 2007
Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors
Kiev S Ly, Michael A Letavic, John M Keith, et al.
Molecular Pharmacology
|
July 20, 2002
Behavioral characterization of mice lacking histamine H(3) receptors
Hiroshi Toyota, Christine Dugovic, Muriel Koehl, et al.
Molecular Genetics and Metabolism
|
May 3, 2016
Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions
Elsa Shapiro, Jessica Bernstein, Heather R Adams, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
April 30, 2023
Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double-blind, placebo-controlled phase 1/2 clinical study
S M Rowe, J B Zuckerman, D Dorgan, et al.
The New England Journal of Medicine
|
September 5, 2019
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency
Rachael F Grace, Christian Rose, D Mark Layton, et al.
Page
of 19